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Summary
Background Debate continues about the consequences of adolescent cannabis use. Existing data are limited in 
statistical power to examine rarer outcomes and less common, heavier patterns of cannabis use than those already 
investigated; furthermore, evidence has a piecemeal approach to reporting of young adult sequelae. We aimed to 
provide a broad picture of the psychosocial sequelae of adolescent cannabis use.
Methods We integrated participant-level data from three large, long-running longitudinal studies from Australia and 
New Zealand: the Australian Temperament Project, the Christchurch Health and Development Study, and the 
Victorian Adolescent Health Cohort Study. We investigated the association between the maximum frequency of 
cannabis use before age 17 years (never, less than monthly, monthly or more, weekly or more, or daily) and seven 
developmental outcomes assessed up to age 30 years (high-school completion, attainment of university degree, 
cannabis dependence, use of other illicit drugs, suicide attempt, depression, and welfare dependence). The number 
of participants varied by outcome (N=2537 to N=3765).
Findings We recorded clear and consistent associations and dose-response relations between the frequency of 
adolescent cannabis use and all adverse young adult outcomes. After covariate adjustment, compared with individuals 
who had never used cannabis, those who were daily users before age 17 years had clear reductions in the odds of high-
school completion (adjusted odds ratio 0·37, 95% CI 0·20–0·66) and degree attainment (0·38, 0·22–0·66), and 
substantially increased odds of later cannabis dependence (17·95, 9·44–34·12), use of other illicit drugs 
(7·80, 4·46–13·63), and suicide attempt (6·83, 2·04–22·90).
Interpretation Adverse sequelae of adolescent cannabis use are wide ranging and extend into young adulthood. 
Prevention or delay of cannabis use in adolescence is likely to have broad health and social benefits. Efforts to reform 
cannabis legislation should be carefully assessed to ensure they reduce adolescent cannabis use and prevent 
potentially adverse developmental effects.
Funding Australian Government National Health and Medical Research Council.
Introduction
Marked shifts have taken place in attitudes to cannabis 
use.1 Moves to decriminalise or legalise cannabis use in 
several US states and Latin American countries are a sign 
of such changes in public opinion.2 These shifts have 
happened while debate continues about the long-term 
health and social sequelae of adolescent cannabis use.3,4 
Additionally, in some countries adolescents are initiating 
cannabis use earlier than have those in previous years5 
and more adolescents are using cannabis heavily.6–8 In 
England, 4% of 11–15 year olds are past-month cannabis 
users;7 about 7% of US high-school seniors are daily or 
near-daily cannabis users;8 and in Australia, less than 1% 
of 14–19 year olds use daily and 4% use weekly.6 This 
prevalence is particularly concerning because adolescence 
seems to be a vulnerable developmental period for the 
consequences of cannabis exposure,9 and evidence 
suggests that early use of cannabis is associated with 
increased risk of adverse developmental outcomes.10–14
Persisting questions about the long-term effects of 
adolescent cannabis use have clouded debate.12,15,16 The 
existing evidence has limitations, including limited 
statistical power to examine rarer outcomes and less 
common, more regular patterns of cannabis use than 
those already assessed; insufficient control for con-
founding; and a tendency to examine only one outcome 
or domain. As such, the picture of adolescent cannabis 
use and its putative health consequences is fractured. We 
address this issue through the integration of data from 
three large, long-running longitudinal studies from 
Australia and New Zealand: the Australian Temperament 
Project (ATP),17 the Christchurch Health and Develop-
ment Study (CHDS),18 and the Victorian Adolescent 
Health Cohort Study (VAHCS).19
In this integrative meta-analysis, we examined the 
long-term sequelae of adolescent cannabis use on 
important domains of wellbeing during the transition to 
adulthood. Specifically, we aimed to develop similar 
measures of cannabis use and each outcome across all 
cohorts; examine the association between patterns of 
use before age 17 years and each outcome in combined 
data; and adjust the associations reported for a wide 
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range of potential confounding factors drawn from 
similar domains across studies spanning individual, 
family, and peer characteristics and behaviours.
Methods
Design and participants
Integrative analyses were developed across the ATP, 
CHDS, and VAHCS (appendix). The analyses were based 
on data obtained over relevant assessments (appendix) 
between ages 13 and 30 years. We chose these cohorts 
because they had similar measures of cannabis use and 
outcomes that allowed effective harmonisation. We 
integrated participant-level data rather than using the 
more common meta-analytic approach of combining 
study-level estimates. This approach had at least three 
advantages: increased sample size and statistical 
precision,20,21 the opportunity to include a wide range of 
potential confounding factors, and the ability to provide a 
broad picture of the health and psychosocial consequences 
of adolescent cannabis use.
Measures and outcomes
Studies varied in measures used to assess cannabis use 
and outcomes, assessment period (eg, past month, past 
year), and timings of assessment. However, sufficient 
commonalities existed to enable integration of data22,23 and 
development of measures that were consistent across 
studies.22,23 We assessed seven outcomes in young people 
aged between 17 and 30 years, spanning educational 
attainment, substance use, mental health, and welfare 
dependence. The number of participants varied by 
outcome (from 2537 to 3765 participants). We chose the 
outcomes on the basis of previous research that established 
a link between a given outcome and cannabis use, and the 
availability of similar outcome measures across the 
cohorts. Derivation of the harmonised variables is 
summarised below, with additional information in the 
appendix. All dichotomous variables were coded as 0 for 
no and 1 for yes.
All studies included measures of frequency of cannabis 
use during mid-adolescence (appendix). We created a 
five-level measure of the maximum frequency of 
cannabis use before age 17 years (with 0 as never, 1 as less 
than monthly, 2 as monthly or more, 3 as weekly or more, 
and 4 as daily).
All studies obtained data for the completion of high 
school and university degree attainment. We created a 
dichotomous measure of high-school completion, and 
university degree attainment, both by age 25 years.
All studies included a measure of symptoms of 
cannabis dependence in the past 12 months. The CHDS 
and VAHCS assessed cannabis dependence with the 
Composite International Diagnostic Interview. The 
ATP obtained data for the frequency of five symptoms 
of cannabis dependence. We created a dichotomous 
measure of cannabis dependence in the past 12 months 
between ages 17 and 25 years.
All studies obtained data about use of other illicit drugs 
in the past month or past year from several categories: 
inhalants, hallucinogens, ecstasy, amphetamines, 
methamphetamines, heroin, cocaine, and non-medical 
use of prescription drugs. We created a dichotomous 
measure for use of other illicit drugs in the past month to 
the past year by ages 23–25 years.
The CHDS assessed number of suicide attempts at 
yearly intervals from ages 17 to 25 years. The VAHCS 
used the Beck Self-harm Inventory at seven assessment 
times between ages 16 and 29 years (on average). On the 
basis of specific items, participants who reported self-
harm with a serious intention to end life (eg, suicide 
attempt) were categorised. We created a dichotomous 
measure of any suicide attempt made between ages 17 
and 25 years for the CHDS and VAHCS. The ATP did not 
assess suicidal behaviour.
The studies all used different measures to assess 
depression, and completed assessments at different ages. 
The CHDS used the Composite International Diagnostic 
Interview, the VAHCS used the Clinical Interview 
Schedule, and the ATP used the depression subscale 
from the short-form Depression Anxiety Stress Scale. We 
created a dichotomous measure of moderate or severe 
depression in the past week to the past month between 
ages 17 and 25 years.
The studies obtained data about present main source of 
income, including various categories of government 
support. Because patterns of income are not typically 
established until the late 20s,24 we used data from the ATP 
at ages 27–28 years, data from the VAHCS at age 29 years, 
and data from the CHDS at age 30 years. We created a 
dichotomous measure of present welfare dependence 
(excluding education-related government support) at ages 
27–30 years.
We noted small between-study variations in the 
prevalence of adolescent cannabis use and some 
outcomes (appendix) that might be expected to be present 
in cohorts obtained from regions of similar cultural and 
sociodemographic backgrounds.
We selected potential confounding factors from each 
study on the basis of previous research suggesting that the 
variables might be correlated with both cannabis use and 
adverse psychosocial outcomes. These confounding factors 
spanned individual background and functioning, and 
parental and peer factors. Factors assessed  antecedent to 
cannabis use were included when available. The appendix 
provides further information about potential confounding 
factors.
Statistical analysis
The analysis was based on an integrated dataset that 
combined participant-level data from the cohorts. The 
analysis was conducted in four stages. First, we estimated 
association between extent of adolescent cannabis use and 
each outcome with data from each study and from the 
combined dataset. This analysis examined associations 
See Online for appendix
For more on the ATP see http://
www.aifs.gov.au/atp
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between the extent of adolescent cannabis use and each 
outcome with data from each study and from the 
combined dataset. We tested associations for significance 
by fitting logistic regression models to the data from each 
study and from the combined dataset in which the log 
odds of each outcome were modelled as a linear function 
of the five-level measure of frequency of cannabis use. 
The models for the combined data were of the form: 
logit (Yij)=B0j + B1Xij where logit (Yij) was the log odds of 
the outcome Y for individual i in study j (j=1, 2, 3), and Xij 
was the corresponding frequency of cannabis use for 
individual i in study j. The slope parameter for cannabis 
use (B1) was assumed to be constant across studies. 
However, the model included study-specific random 
intercepts (B0j) to allow for random sources of between-
study heterogeneity that were not otherwise represented 
in the model. We obtained effect-size estimates (odds 
ratios [ORs] and 95% CIs) for the combined data pooled 
over studies.
Second, we adjusted for covariates. To account for 
confounding factors, we extended the models in the first 
equation to include these factors. These models were of 
the form: logit (Yij)=B0j + B1Xij + ΣBkjZikj where Zkj was 
a series of covariate factors representing the complete set 
of covariates across all studies j. Overall, we included 
53 factors (appendix), but not all these covariates were 
measured by all studies. To address this inconsistency we 
developed a null covariate model. In this model if a 
Never Less than monthly Monthly or more Weekly or more Daily p value*
High-school completion
ATP 833/897 (93%) 89/100 (89%) 87/102 (85%) 24/35 (69%) 2/2 (100%) <0∙0001
CHDS 307/618 (50%) 106/276 (38%) 18/63 (29%) 11/82 (13%) 0/7 <0∙0001
VAHCS 851/977 (87%) 229/282 (81%) 74/90 (82%) 85/108 (79%) 24/39 (62%) <0∙0001
Combined data 1991/2492 (80%) 424/658 (64%) 179/255 (70%) 120/225 (53%) 26/48 (54%) <0∙0001
Degree attainment
ATP 359/734 (49%) 23/82 (28%) 22/74 (30%) 8/27 (30%) 0/3 <0∙0001
CHDS 181/596 (30%) 57/257 (22%) 11/63 (18%) 5/74 (7%) 0/7 <0∙0001
VAHCS 415/978 (42%) 89/283 (32%) 23/90 (26%) 13/108 (12%) 6/39 (15%) <0∙0001
Combined data 955/2308 (41%) 169/622 (27%) 56/227 (25%) 26/209 (12%) 6/49 (12%) <0∙0001
Cannabis dependence
ATP 25/600 (4%) 4/64 (6%) 10/55 (18%) 11/22 (50%) 2/2 (100%) <0∙0001
CHDS 17/619 (3%) 25/276 (9%) 12/64 (19%) 42/82 (51%) 6/7 (86%) <0∙0001
VAHCS 33/912 (4%) 27/259 (10%) 17/83 (21%) 45/99 (46%) 15/33 (46%) <0∙0001
Combined data 75/2131 (4%) 56/599 (9%) 39/202 (19%) 98/203 (48%) 23/42 (55%) <0∙0001
Other illicit drug use
ATP 88/738 (12%) 18/82 (22%) 17/75 (23%) 12/28 (43%) 1/3 (33%) <0∙0001
CHDS 80/596 (13%) 83/257 (32%) 29/63 46%) 31/74 (42%) 5/7 (71%) <0∙0001
VAHCS 41/972 (4%) 26/282 (9%) 19/89 (21%) 31/107 (29%) 9/39 (23%) <0∙0001
Combined data 209/2306 (9%) 127/621 (21%) 65/227 (29%) 74/209 (35%) 15/49 (31%) <0∙0001
Suicide attempt†
CHDS 26/619 (4%) 18/276 (7%) 6/64 (9%) 13/82 (16%) 1/7 (14%) <0∙001
VAHCS 3/972 (<1%) 1/282 (<1%) 4/90 (4%) 5/107 (5%) 1/38 (3%) <0∙001
Combined data 29/1591 (2%) 19/558 (3%) 10/154 (7%) 18/189 (10%) 2/45 (4%) <0∙001
Depression
ATP 47/898 (5%) 4/98 (4%) 2/102 (2%) 2/34 (6%) 1/3 (33%) 0∙661
CHDS 80/619 (13%) 48/276 (17%) 11/64 (17%) 20/82 (24%) 1/7 (14%) 0∙006
VAHCS 94/1041 (9%) 25/288 (9%) 13/100 (13%) 10/114 (9%) 5/39 (13%) 0∙437
Combined data 221/2558 (9%) 77/662 (12%) 26/266 (10%) 32/230 (14%) 7/49 (14%) 0∙032
Welfare dependence‡
ATP 26/735 (4%) 5/83 (6%) 2/75 (3%) 0/32 0/3 0∙491
CHDS 41/581 (7%) 17/258 (7%) 4/61 (7%) 16/72 (22%) 3/7 (43%) <0∙0001
VAHCS 77/895 (9%) 19/259 (7%) 10/90 (11%) 9/93 (10%) 4/40 (10%) 0∙578
Combined data 144/2211 (7%) 41/600 (7%) 16/226 (7%) 25/197 (13%) 7/50 (14%) 0∙012
Data are n/N (%). ATP=Australian Temperament Project. CHDS=Christchurch Health and Development Study. VAHCS=Victorian Adolescent Health Cohort Study. *p value of 
the association between adolescent cannabis use and each outcome in each study, and in combined data adjusted for study-specific effects. †The ATP did not assess suicidal 
behaviour. ‡Assessed at age 28–30 years. 
Table 1: Outcomes according to maximum frequency of cannabis use before age 17 years in each study and when data were combined
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covariate was not noted for any study, we set this covariate 
to a value of zero for that study. The advantage of this 
approach is that it included all the available data in the 
analysis. The appendix provides further information 
about this approach. We obtained estimates of the pooled 
adjusted ORs and 95% CIs.
The above models assumed a linear effect of cannabis 
use on the log odds of each outcome, and a common slope 
parameter (B1) for the effect of cannabis use across studies. 
To test these assumptions, we extended the above adjusted 
models in two ways. We first did Wald χ² tests to examine 
the improvement in fit of a categorical representation of 
cannabis use over and above the linear model for each 
outcome. In all cases a linear model provided an adequate 
representation of the effect of cannabis use and no 
significant departures from linearity were detected. We 
then extended the models to allow the slope parameter for 
cannabis use (B1) to vary across studies, and then we did 
Wald χ² tests to test for between-study heterogeneity in the 
effect of cannabis use. In all cases these tests were non-
significant, suggesting that the assumption of a common 
slope was justified for all outcomes.
For the third stage of the statistical analysis, we did a 
sensitivity analysis.  Although the null covariate model 
offered the advantage of enabling analysis of all available 
data, this method could have introduced study-specific 
biases. To examine the robustness of the null covariate 
model, we compared results with four alternative estimates 
of the adjusted ORs, which we derived with a harmonised 
covariate approach using a reduced set of covariates 
common to all studies; a covariate score approach in which 
we used the covariate information in each study to derive an 
optimum predictor of each outcome, and the single 
predictor score as a covariate in the combined data; a 
propensity score approach in which we used the covariate 
data in each study to derive a prediction model for adolescent 
cannabis use, and included the estimated propensity score 
as a covariate for each study; and a standard meta-analytic 
approach in which covariate-adjusted analyses were done 
separately for each study, and the study-level result then 
pooled meta-analytically (appendix). Fourth, we investigated 
the potential for selection bias. We used multiple imputation 
to examine the implications of possible selection bias 
attributable to sample attrition and missing data (appendix).
We did all analyses with STATA SE (version 13).
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Table 1 shows the associations between frequency of 
cannabis use before age 17 and the outcomes in young 
adults in each study and in the combined dataset, and the 
tests of significance from the fitted regression models for 
each outcome. At the individual study level, we recorded 
evidence of significant associations for all outcomes, 
except depression and welfare dependence in ATP and 
VAHCS (table 1). For the combined data, all associations 
were significant, with clear evidence of a dose-response 
association in which increasing frequency of adolescent 
cannabis use was associated with declining rates of high-
school completion and degree attainment, and increasing 
risks of cannabis dependence, other illicit drug use, 
suicide attempt, depression, and welfare dependence. 
Table 2 and figure 1 show estimates of effect size for each 
level of cannabis use estimated from the regression 
model fitted to the combined data for each outcome.
We adjusted the associations in table 1 for confounding 
by adding the relevant covariates for each study with the 
null covariate adjustment approach. We included 
53 covariate factors from the three studies in the analysis. 
These covariates spanned individual background and 
functioning, and measures of parental and peer factors 
(appendix). Table 2 and figure 2 show the adjusted ORs 































































































































































Data are odds ratios (95% CIs). *Only the Christchurch Health and Development Study and the Victorian Adolescent 
Health Cohort Study assessed suicidal behaviour. †Assessed at age 28–30 years.
Table 2: Maximum frequency of cannabis use before age 17 years, and each young adult outcome in 
combined data, before and after adjustment with the null covariate approach
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Figure 1: Unadjusted odds 
ratios (log scale) between 
maximum frequency of 
cannabis use before age 
17 years and young adult 
outcomes in combined 
data, compared with 
individuals who have never 
used cannabis
Error bars show 95% CIs.
Figure 2: Adjusted odds 
ratios (log scale) between 
maximum frequency of 
cannabis use before age 
17 years and young adult 
outcomes in combined 
data, compared with 
individuals who have never 
used cannabis
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between the extent of cannabis use and each outcome in 
the combined data. After adjustment, the associations for 
depression and welfare dependence were both non-
significant and negligible in size (table 2). For all other 
outcomes the associations remained significant (table 2). 
The estimates for adjusted ORs suggested that individuals 
who were daily users before age 17 years had odds of 
high-school completion and degree attainment that were 
63% and 62% lower, respectively, than those who had 
never used cannabis; furthermore, daily users had odds 
of later cannabis dependence that were 18 times higher, 
odds of use of other illicit drugs that were eight times 
higher, and odds of suicide attempt that were seven times 
higher (table 2, figure 2).
Results of Wald χ² tests of between-study heterogeneity 
in the effect of cannabis use were non-significant (data 
not shown), suggesting that the associations were similar 
across studies for all outcomes.
To examine the sensitivity of the results for adjusted 
ORs in table 2 to choice of model for adjusting covariates, 
we repeated the analyses with four alternative approaches 
to covariate adjustment: harmonised covariate, covariate 
score, propensity score, and standard meta-analysis 
(appendix). The findings from table 2 were replicated by 
these analyses, showing that the results were not 
dependent on the methodology used to estimate the 
covariate-adjusted associations. Further analysis using 
multiple imputation of missing data to control for 
potential sample selection bias produced findings that 
were entirely consistent with those of the recorded data 
(appendix).
Discussion
Our findings show clear and consistent associations 
between the frequency of adolescent cannabis use and all 
adverse young adult outcomes. These associations had 
dose-response characteristics across all seven outcomes, 
with the strongest effects shown for daily users. For all 
but two outcomes, associations were resilient to control 
for the range of potential confounding factors assessed. 
With control for potential observed confounders, the 
strength of association substantially reduced, and five of 
the outcomes remained significant. After adjustment, 
individuals who had used cannabis daily before age 
17 years had odds of high-school completion and degree 
attainment that were lower than those who had never 
used cannabis before age 17 years, and higher odds of 
cannabis dependence, use of other illicit drugs, and 
suicide attempt. Results were robust to four alternative 
approaches to covariate adjustment and imputation of 
missing data.
Several aspects of the study findings support the 
possibility of a causal relation. First, we recorded strong 
associations between adolescent cannabis use and all 
young adult outcomes investigated. Second, the 
associations had dose-response characteristics with 
increasing frequency of adolescent use. Third, most 
associations were resilient to control for potential 
confounding factors present before and during 
adolescence. Studies such as ours are limited in their 
capacity to explain the mechanisms behind such 
associations, although some research has suggested that 
heavy cannabis use in adolescence might affect CNS 
development;9 alternatively, cannabis use in adolescence 
could be a marker of developmental trajectories that place 
young people at increased risk of adverse psychosocial 
outcomes.25 Study findings in relation to high-school 
completion, university degree attainment, cannabis 
dependence, and use of other illicit drugs are consistent 
with previous research investigating the association 
between early cannabis use and these outcomes.10,12,13,23 
Although the association between cannabis use and 
high-school completion probably does not arise from a 
reverse causal association (school dropout leading to 
cannabis use),26 this possibility remains plausible.10 The 
strong adjusted effects noted for suicide attempt add to a 
small body of research that supports a more direct 
relation between cannabis use and suicidal ideation.27 
Depression and welfare dependence were not significantly 
associated with adolescent cannabis use after adjustment. 
This finding is consistent with previous reviews, which 
concluded that the effect of cannabis use on these 
psychosocial outcomes could plausibly be explained by 
Panel: Research in context
Systematic review
We did a review of systematic reviews published since the key 2004 paper by Macleod and 
colleagues.15 We searched Medline, Global Health, Embase, PsycINFO, and PsycARTICLES 
with the terms “cannabis or marijuana” and “systematic review” for reports about the 
effect of cannabis use on psychosocial outcomes (eg, school or university completion, 
welfare dependence), cannabis dependence, use of other illicit drugs, depression, and 
suicide. We identified 290 non-duplicate reports, of which nine focused on our key 
outcomes. Both cross-sectional and longitudinal data link cannabis use with high-school 
dropout, although reverse causality (dropout leading to cannabis use) remains plausible.10 
Although no review of welfare dependence was identified, existing data from our study 
cohorts link cannabis use with welfare dependence and unemployment.11 Use of cannabis 
is associated with development of both cannabis dependence and use of other illicit 
drugs.12,13 Although a causal association with depression is in doubt,12,16 heavy use in 
particular, increases the odds of depression.14 Initial reports also suggest that prenatal 
exposure effects subsequent depression.34 Presently, evidence is insufficient to cite a 
causal link with suicide.35
Interpretation
Study findings suggest that adolescent cannabis use is linked to difficulties in successfully 
completing the tasks that mark the transition to adulthood. Prevention or delay of 
cannabis use in adolescence is likely to have broad health and social benefits. The findings 
are relevant given the movement in some countries to decriminalise or legalise cannabis 
raising a possibility that cannabis might become more accessible to young people. In the 
rapidly changing political and legislative landscape, protection of adolescents from the 
potential adverse effects of cannabis use is an important facet of legislative reforms for 
cannabis. Efforts to reform cannabis legislation should be carefully assessed to ensure 
they reduce adolescent cannabis use and prevent potentially adverse effects on 
adolescent development.
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potential confounding factors that had not been 
adequately controlled for in studies to date.15, 16
This study has some limitations. First, there was some 
between-study variation in the levels of the outcomes, 
which could have been shown by variations in estimates of 
effect size across studies. However, such estimates were 
very similar, with Wald tests providing no evidence of 
significant between-study heterogeneity. Second, the 
criteria for depression in the Australian Temperament 
Study were weaker than those in other studies. However, 
irrespective of the way in which depression was measured, 
the same conclusion holds. Third, although we controlled 
for many potential confounding factors, the possibility 
that the recorded associations might show the effects of 
unmeasured or uncontrolled confounding cannot be 
completely ruled out.15 Residual confounding could 
attenuate the associations. However, analyses that have 
used fixed-effects regression to control for non-observed 
confounders suggest that associations between cannabis 
use and various outcomes persist.28,29 Methods of fixed-
effects regression30 provide a means to control for non-
observed fixed sources of confounding of the associations 
between an exposure variable and an outcome in repeated 
measures data. Fourth, measures were obtained by self-
report, which might be subject to socially desirable 
response bias, the extent of which can vary with age.31 
Presence of such bias could lead to over-reporting or 
under-reporting of cannabis use. In face-to-face settings 
(as is generally the case for the cohorts in this study) 
adolescents might be more likely than adults to under-
report risk behaviours;31 however, under-reporting would 
attenuate any observable associations. Fifth, similarities in 
the cultural and social context and epidemiology of 
cannabis use between Australia and New Zealand suggest 
that results can be applied to Australasian populations. 
Because rates of cannabis use in young people in 
Australasia are similar to those in other high-income 
countries (eg, in the USA, Canada, and the UK),32,33 
generalisability of findings to those settings is supported. 
Nevertheless, the social and legislative context of cannabis 
use varies between regions,2 and remains an important 
consideration in the generalisation of these findings.
This study extends previous research of the link between 
adolescent cannabis use and problems later in life by the 
integration of data from various sources and the provision 
of control for a broader range of covariates than possible in 
traditional meta-analyses. The findings provide evidence of 
the potential harms of adolescent cannabis use across 
several domains. The prevention or delay of cannabis use 
in adolescence might have broad health and social benefits. 
The findings are particularly relevant as the movement to 
decriminalise or legalise cannabis gathers momentum in a 
number of countries (panel).2 Research suggests that such 
changes could lead to an increase in cannabis use mainly 
through a reduction in price.36 Although the effect of 
cannabis prices on the intensity and duration of cannabis 
use is unclear,36 evidence suggests that lower prices might 
lead to earlier onset of use.37 This hypothesis is concerning 
because the adolescent brain is vulnerable to the effects of 
cannabis9 and, as our findings suggest, cannabis use in 
adolescence is associated with increased risk of adverse 
developmental outcomes. In the rapidly changing political 
and legislative landscape, protection of adolescents from 
the potentially adverse effects of cannabis use is an 
important facet of cannabis legislative reforms. Despite 
increased availability of cannabis (for medical use) in some 
US states, a study38 showed no increase in use among 
young people in those states. Nonethelss, efforts to reform 
cannabis legislation should be carefully assessed to ensure 
they reduce adolescent cannabis use and prevent potentially 
adverse developmental effects.
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Present or previous cannabis use is more common in 
individuals with low educational attainment than in 
those with higher levels of educational achievement. 
Debate surrounds whether this association is 
attributable to cannabis use being more frequent in 
socioeconomic groups that are more likely to have 
poor educational attainment, whether cannabis 
use is actually a marker of an already established 
disadvantageous development, or whether the 
association is a truly causal one.1
In The Lancet Psychiatry, Edmund Silins and colleagues’ 
integrative meta-analysis2 assesses the long-term 
psycho social sequelae of adolescent cannabis use. The 
report, which is based on participant-level data from 
three studies from Australia and New Zealand, clearly 
shows a dose–response association between frequency 
of cannabis use in adolescence and ability to complete 
specific tasks that mark the transition to adulthood, 
specifically the ability to achieve high levels of education. 
After confounder control, individuals who were daily 
users before age 17 years had reductions in the odds 
of high-school completion (adjusted odds ratio [OR] 
0·37, 95% CI 0·20–0·66) and degree attainment (0·38, 
0·22–0·66) compared with those who had never used 
cannabis. Furthermore, cannabis use was associated 
with increased risk of suicide attempt (adjusted OR 6·83, 
95% CI 2·04–22·90) and, unsurprisingly, later cannabis 
dependence (17·95, 9·44–34·12) and use of other illicit 
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drugs (7·80, 4·46–13·63). The participation rate in the 
study is impressive, the attrition rates are modest, and 
the number of confounding factors, assessed across 
cohorts, is overwhelming and covers a broad range of 
factors that could affect outcome independently.
Persistent cannabis use has adverse effects, such 
as low energy and initiative, and impairment of 
cognitive functions, and these factors are likely to 
mediate the harmful effect of cannabis on educational 
attainment. Findings from randomised clinical 
trials show a negative short-term effect of cannabis 
intake compared with placebo on cognitive function 
during, and in the hours following, intoxication. 
Compared with placebo, dronabinol impaired working 
memory and verbal fluency in a trial3 involving 
22 healthy volunteers. In another trial4 with 30 healthy 
participants, Morrison and colleagues showed that 
working memory and executive functions were 
reduced by 10–20% in participants randomised to 
receive dronabinol.
A randomised clinical trial that exposes some 
young people to cannabis in various doses for a 
long term and compares them with other young 
people given placebo will never be done. Therefore, 
findings from naturalistic experiments will be relied 
on to obtain knowledge about whether the harmful 
effect on cognitive function is temporary. Increasing 
evidence shows that brain development during 
adolescence can be harmed by frequent cannabis use, 
and cognitive functions can be permanently reduced. 
In the Dunedin birth cohort5 cognitive function 
was examined at age 13 years and again at age 
38 years. Continuous cannabis use was associated 
with neuropsychological decline across all domains 
of cognitive functioning, and more persistent use 
was associated more severe decline. Additionally, 
adolescent-onset cannabis users were more impaired 
than adult-onset users and neuropsychological 
functioning in adolescent-onset users was not fully 
restored after cessation. The investigators concluded 
that their findings were suggestive of a neurotoxic 
effect of cannabis on the adolescent brain.
In a review,6 Schweinsburg and colleagues concluded 
that studies of adolescents who were heavy marijuana 
users showed that there were still persisting deficits at 
least 6 weeks after discontinuation, particularly in the 
domains of learning, memory, and working memory. 
Moreover, cognitive functions were more severely affected 
in adolescents than in adults.
Cannabis use in adolescence has also been associated 
with increased risk of psychosis in adulthood.7 Cannabis 
use is associated with earlier onset of psychosis,8 and 
in patients with cannabis use and psychosis, risk of 
continuous psychotic symptoms is higher in those who 
continue to use cannabis than in those who stop .9
The convincing results presented by Silins and 
colleagues2 are very valuable and highly appropriate 
at a time when several American states and countries 
in Latin America and Europe have decriminalised or 
legalised cannabis and allow unrestricted marketing 
of various formulations of the drug. Such changes 
in legislation will probably be followed by decreased 
prices and increased use, which will lead to more young 
people having difficulties with school completion and 
social and personal maturation, and will increase the 
risk of psychosis.
Youth is a very vulnerable period in life. Socially, 
young people need to develop and mature, and 
to prepare themselves to meet demands in their 
adult life, such as completing education and finding 
employment, choosing leisure activities, and finding 
partners and friends. Cannabis use, especially frequent 
uses, impairs this development and reduces the likeli-
hood that a young person will be able to establish a 
satisfactory adult life.
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